New RSV vaccines OK'd for high-risk groups, thanks to UI tri

Although the common and highly-contagious RSV – short for “respiratory syncytial virus” – runs a mild, cold-like course for most people, it can hit infants and patients over 60 hard, even requiring hospitalization. For the first time, a vaccine is how available for those high-risk groups – thanks, in part, to University of Iowa Health Care trial work.

Related Keywords

United States , University Of Iowa , Iowa , University Of Iowa Health Care , Iowans , Pat Winokur , Patricia Winokur , Steve Varga , Christina Kopp , Ui Carver College Of Medicine , Ui Health Care , Us Centers For Disease , Pfizer , University Of Iowa Hospitals , Food Drug Administration , Iowa Health Care , Disease Control , Drug Administration , Daily News , Iowa Hospitals ,